New risk model may let some NPC patients avoid unnecessary chemo

This study tests a personalized approach for people with advanced nasopharyngeal cancer. After standard chemoradiation, some patients get extra therapy to prevent the cancer from returning. But this extra therapy can cause side effects. The trial uses a new risk model (RAIRI) to identify patients who are at low risk of recurrence. Those patients would skip the extra therapy and just be monitored. The goal is to see if this personalized strategy is as safe and effective as giving everyone extra therapy. About 651 participants will be enrolled across multiple centers.